Share Price and Basic Stock Data
Last Updated: November 20, 2025, 9:25 pm
| PEG Ratio | -6.83 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Archean Chemical Industries Ltd operates in the inorganic chemicals sector, focusing on specialty chemicals. The company reported a market capitalization of ₹6,830 Cr and a current stock price of ₹554. The revenue from operations for the fiscal year ending March 2023 was ₹1,441 Cr, which represents a growth trajectory from ₹1,130 Cr in FY 2022. However, there was a decline in revenue for FY 2024, which stood at ₹1,330 Cr, and further dropped to ₹1,014 Cr for FY 2025. Quarterly sales figures illustrate volatility, with sales peaking at ₹400 Cr in June 2022 and declining to ₹290 Cr by September 2023. This fluctuation suggests that while the company has experienced growth in the past, recent quarters have seen challenges in sustaining revenue levels, indicating potential market pressures or operational hurdles. The trailing twelve months (TTM) revenue stood at ₹1,081 Cr, reflecting a need for strategic adjustments to stabilize and enhance sales performance moving forward.
Profitability and Efficiency Metrics
Archean Chemical Industries reported a net profit of ₹188 Cr for the TTM period, with a notable decline from ₹384 Cr in FY 2023 to ₹322 Cr in FY 2024 and ₹185 Cr in FY 2025. The operating profit margin (OPM) has shown variability, peaking at 51% in March 2023 but declining to 28% in March 2025. This indicates challenges in maintaining cost efficiency amidst fluctuating sales. The company’s return on equity (ROE) stood at 12%, while the return on capital employed (ROCE) was reported at 16%, lower than typical sector benchmarks, which often range between 15%-20%. Additionally, the interest coverage ratio (ICR) reported an impressive 43.37x, indicating strong ability to meet interest obligations. However, the cash conversion cycle (CCC) has lengthened to 62 days, suggesting potential inefficiencies in managing receivables and inventory, which could impact liquidity if not addressed effectively.
Balance Sheet Strength and Financial Ratios
The balance sheet of Archean Chemical Industries illustrates a robust financial position, with no reported borrowings, highlighting a debt-free status that reduces financial risk. The company’s price-to-book value (P/BV) ratio stood at 3.41x, indicating a premium valuation relative to its book value per share of ₹151.02. The current ratio was reported at 3.50, suggesting strong short-term liquidity, while the quick ratio of 2.65 reinforces this liquidity position. The operating profit for FY 2025 was ₹323 Cr, down from ₹634 Cr in FY 2023, which may raise concerns regarding operational efficiency. Despite the declining trend in profits, the low long-term debt-to-equity ratio of 0.08 signals a conservative capital structure. However, the decline in net profit margins from 26.54% in FY 2023 to 15.57% in FY 2025 indicates potential challenges in profitability that could affect investor sentiment.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Archean Chemical Industries reflects a diverse ownership structure, with promoters holding 53.44% of the company, indicating strong control and commitment. Institutional investors hold a significant stake, with foreign institutional investors (FIIs) at 11.16% and domestic institutional investors (DIIs) at 25.51%. Notably, the number of shareholders has increased from 49,606 in December 2022 to 70,852 by September 2025, indicating growing retail interest. However, the gradual decline in DII holdings from a peak of 30.78% in June 2023 to 24.69% in June 2025 may raise concerns about institutional confidence in the company. The public shareholding has also decreased to 9.90%, which could suggest a consolidation of shares among larger investors. This pattern may reflect a cautious approach by the market towards the company’s recent performance and future prospects.
Outlook, Risks, and Final Insight
The outlook for Archean Chemical Industries is mixed, with potential for recovery contingent on operational improvements and market conditions. Strengths include a debt-free balance sheet, a solid interest coverage ratio, and a strong liquidity position, which provide resilience in challenging times. However, the company faces risks, including declining sales trends, increasing cash conversion cycles, and diminishing profit margins, which could strain financial performance. To enhance investor confidence and profitability, Archean may need to focus on operational efficiencies, cost management, and strategic market positioning. If the company can successfully navigate these challenges, it may stabilize its revenue and profit trajectory, potentially leading to improved shareholder value. Conversely, failure to address these issues could result in continued volatility, impacting investor sentiment and overall market performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Archean Chemical Industries Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Fischer Medical Ventures Ltd | 2,776 Cr. | 42.9 | 125/42.9 | 138 | 5.55 | 0.01 % | 1.08 % | 0.70 % | 1.00 |
| Emmessar Biotech & Nutrition Ltd | 15.5 Cr. | 31.0 | 48.3/25.8 | 67.4 | 16.0 | 0.00 % | 12.6 % | 4.23 % | 10.0 |
| Cochin Minerals & Rutile Ltd | 209 Cr. | 266 | 410/238 | 12.4 | 211 | 3.00 % | 23.3 % | 15.0 % | 10.0 |
| Archean Chemical Industries Ltd | 6,830 Cr. | 554 | 730/408 | 33.3 | 157 | 0.54 % | 16.0 % | 12.0 % | 2.00 |
| Alufluoride Ltd | 353 Cr. | 451 | 536/376 | 17.2 | 144 | 0.66 % | 23.6 % | 20.8 % | 10.0 |
| Industry Average | 4,991.50 Cr | 580.54 | 175.63 | 160.00 | 0.49% | 13.95% | 10.65% | 7.00 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 400 | 293 | 365 | 382 | 343 | 290 | 413 | 283 | 211 | 238 | 243 | 322 | 279 |
| Expenses | 239 | 175 | 205 | 188 | 208 | 195 | 267 | 195 | 139 | 162 | 158 | 232 | 196 |
| Operating Profit | 161 | 119 | 160 | 194 | 135 | 96 | 146 | 88 | 73 | 76 | 84 | 90 | 83 |
| OPM % | 40% | 40% | 44% | 51% | 39% | 33% | 35% | 31% | 34% | 32% | 35% | 28% | 30% |
| Other Income | 9 | 19 | 8 | 9 | 11 | 12 | 10 | 14 | 12 | -26 | 12 | 12 | 13 |
| Interest | 39 | 35 | 19 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 4 |
| Depreciation | 18 | 17 | 17 | 17 | 17 | 17 | 18 | 17 | 18 | 18 | 19 | 19 | 20 |
| Profit before tax | 113 | 86 | 131 | 182 | 125 | 88 | 136 | 82 | 65 | 30 | 75 | 80 | 72 |
| Tax % | 25% | 26% | 25% | 25% | 25% | 24% | 25% | 28% | 26% | 26% | 25% | 27% | 28% |
| Net Profit | 85 | 64 | 98 | 137 | 94 | 66 | 102 | 60 | 48 | 22 | 56 | 58 | 52 |
| EPS in Rs | 8.79 | 6.63 | 7.99 | 11.12 | 7.65 | 5.39 | 8.28 | 4.83 | 3.93 | 1.77 | 4.56 | 4.72 | 4.20 |
Last Updated: August 1, 2025, 7:30 am
Below is a detailed analysis of the quarterly data for Archean Chemical Industries Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 279.00 Cr.. The value appears to be declining and may need further review. It has decreased from 322.00 Cr. (Mar 2025) to 279.00 Cr., marking a decrease of 43.00 Cr..
- For Expenses, as of Jun 2025, the value is 196.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 232.00 Cr. (Mar 2025) to 196.00 Cr., marking a decrease of 36.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 83.00 Cr.. The value appears to be declining and may need further review. It has decreased from 90.00 Cr. (Mar 2025) to 83.00 Cr., marking a decrease of 7.00 Cr..
- For OPM %, as of Jun 2025, the value is 30.00%. The value appears strong and on an upward trend. It has increased from 28.00% (Mar 2025) to 30.00%, marking an increase of 2.00%.
- For Other Income, as of Jun 2025, the value is 13.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Mar 2025) to 13.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 4.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 20.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 19.00 Cr. (Mar 2025) to 20.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 72.00 Cr.. The value appears to be declining and may need further review. It has decreased from 80.00 Cr. (Mar 2025) to 72.00 Cr., marking a decrease of 8.00 Cr..
- For Tax %, as of Jun 2025, the value is 28.00%. The value appears to be increasing, which may not be favorable. It has increased from 27.00% (Mar 2025) to 28.00%, marking an increase of 1.00%.
- For Net Profit, as of Jun 2025, the value is 52.00 Cr.. The value appears to be declining and may need further review. It has decreased from 58.00 Cr. (Mar 2025) to 52.00 Cr., marking a decrease of 6.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 4.20. The value appears to be declining and may need further review. It has decreased from 4.72 (Mar 2025) to 4.20, marking a decrease of 0.52.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:55 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 439 | 566 | 608 | 741 | 1,130 | 1,441 | 1,330 | 1,014 | 1,081 |
| Expenses | 356 | 497 | 460 | 478 | 663 | 807 | 865 | 691 | 748 |
| Operating Profit | 83 | 69 | 148 | 262 | 467 | 634 | 464 | 323 | 333 |
| OPM % | 19% | 12% | 24% | 35% | 41% | 44% | 35% | 32% | 31% |
| Other Income | 6 | 121 | 8 | 14 | 13 | 44 | 47 | 9 | 10 |
| Interest | 102 | 114 | 122 | 130 | 162 | 97 | 10 | 9 | 12 |
| Depreciation | 73 | 47 | 52 | 55 | 67 | 69 | 70 | 73 | 75 |
| Profit before tax | -85 | 29 | -17 | 90 | 251 | 513 | 431 | 250 | 256 |
| Tax % | -7% | -41% | 105% | 26% | 25% | 25% | 25% | 26% | |
| Net Profit | -79 | 41 | -36 | 67 | 189 | 384 | 322 | 185 | 188 |
| EPS in Rs | -79.16 | 21.31 | -18.50 | 34.56 | 19.58 | 31.18 | 26.12 | 14.98 | 15.25 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 8% | 11% | 20% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 151.90% | -187.80% | 286.11% | 182.09% | 103.17% | -16.15% | -42.55% |
| Change in YoY Net Profit Growth (%) | 0.00% | -339.70% | 473.92% | -104.02% | -78.91% | -119.32% | -26.40% |
Archean Chemical Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 11% |
| 3 Years: | -4% |
| TTM: | -10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 52% |
| 3 Years: | 5% |
| TTM: | -20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -6% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 27% |
| 3 Years: | 22% |
| Last Year: | 12% |
Last Updated: September 5, 2025, 2:21 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 22 | 43 | 27 | 34 | 49 | 30 | 43 | 62 |
| Inventory Days | 830 | 238 | 999 | 532 | ||||
| Days Payable | 1,035 | 398 | 1,689 | 415 | ||||
| Cash Conversion Cycle | -183 | -116 | -663 | 34 | 49 | 30 | 160 | 62 |
| Working Capital Days | -70 | 0 | -38 | 22 | 50 | 41 | 54 | 92 |
| ROCE % | 3% | 13% | 24% | 39% | 46% | 27% | 16% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Small Cap Fund | 4,400,000 | 1.12 | 278.74 | 4,400,000 | 2025-04-22 14:12:24 | 0% |
| SBI Multicap Fund | 4,094,476 | 1.77 | 259.39 | 4,094,476 | 2025-04-22 15:56:51 | 0% |
| DSP Small Cap Fund | 2,297,376 | 1.05 | 145.54 | 2,297,376 | 2025-04-22 15:56:51 | 0% |
| Nippon India Small Cap Fund | 1,373,373 | 0.19 | 87 | 1,373,373 | 2025-04-22 15:56:51 | 0% |
| HDFC Multi Cap Fund | 1,095,175 | 0.59 | 69.38 | 1,095,175 | 2025-04-22 15:56:51 | 0% |
| SBI Magnum Childrens Benefit Fund - Investment Plan | 700,000 | 2.76 | 44.35 | 700,000 | 2025-04-22 15:56:51 | 0% |
| Kotak Small Cap Fund - Regular Plan | 636,952 | 0.28 | 40.35 | 636,952 | 2025-04-22 15:56:51 | 0% |
| Quant Small Cap Fund | 496,073 | 0.2 | 31.43 | 496,073 | 2025-04-22 15:56:51 | 0% |
| ITI Multi Cap Fund | 159,111 | 1.2 | 10.08 | 159,111 | 2025-04-22 15:56:51 | 0% |
| Motilal Oswal Multi Asset Fund | 50,000 | 3.09 | 3.17 | 50,000 | 2025-04-22 15:56:51 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 13.13 | 25.90 | 34.66 | 18.22 |
| Diluted EPS (Rs.) | 13.12 | 25.87 | 34.59 | 18.22 |
| Cash EPS (Rs.) | 19.57 | 31.55 | 36.67 | 26.48 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 151.02 | 137.89 | 116.29 | 26.75 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 151.02 | 137.89 | 116.29 | 26.75 |
| Revenue From Operations / Share (Rs.) | 84.34 | 107.79 | 117.11 | 117.35 |
| PBDIT / Share (Rs.) | 28.47 | 41.00 | 55.04 | 49.78 |
| PBIT / Share (Rs.) | 22.04 | 35.30 | 49.46 | 42.84 |
| PBT / Share (Rs.) | 18.13 | 34.62 | 41.58 | 26.06 |
| Net Profit / Share (Rs.) | 13.14 | 25.85 | 31.09 | 19.54 |
| NP After MI And SOA / Share (Rs.) | 13.14 | 25.85 | 31.09 | 19.54 |
| PBDIT Margin (%) | 33.75 | 38.04 | 46.99 | 42.42 |
| PBIT Margin (%) | 26.13 | 32.75 | 42.23 | 36.50 |
| PBT Margin (%) | 21.49 | 32.11 | 35.50 | 22.20 |
| Net Profit Margin (%) | 15.57 | 23.98 | 26.54 | 16.64 |
| NP After MI And SOA Margin (%) | 15.57 | 23.98 | 26.54 | 16.64 |
| Return on Networth / Equity (%) | 8.69 | 18.74 | 26.73 | 73.02 |
| Return on Capital Employeed (%) | 12.38 | 22.67 | 38.44 | 30.43 |
| Return On Assets (%) | 6.77 | 15.51 | 21.79 | 12.29 |
| Long Term Debt / Equity (X) | 0.08 | 0.03 | 0.00 | 3.27 |
| Total Debt / Equity (X) | 0.09 | 0.03 | 0.01 | 3.28 |
| Asset Turnover Ratio (%) | 0.46 | 0.69 | 0.87 | 0.00 |
| Current Ratio (X) | 3.50 | 5.38 | 3.35 | 2.27 |
| Quick Ratio (X) | 2.65 | 4.44 | 2.37 | 1.58 |
| Inventory Turnover Ratio (X) | 0.42 | 0.32 | 0.31 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 17.37 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 14.23 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 0.00 | 82.63 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 0.00 | 85.77 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 43.37 | 59.80 | 6.99 | 2.97 |
| Interest Coverage Ratio (Post Tax) (X) | 25.97 | 38.70 | 4.95 | 2.16 |
| Enterprise Value (Cr.) | 6487.30 | 8283.52 | 7995.88 | 0.00 |
| EV / Net Operating Revenue (X) | 6.23 | 6.23 | 5.55 | 0.00 |
| EV / EBITDA (X) | 18.46 | 16.37 | 11.81 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 6.11 | 6.22 | 5.56 | 0.00 |
| Retention Ratios (%) | 0.00 | 82.62 | 0.00 | 0.00 |
| Price / BV (X) | 3.41 | 4.86 | 5.60 | 0.00 |
| Price / Net Operating Revenue (X) | 6.11 | 6.22 | 5.56 | 0.00 |
| EarningsYield | 0.02 | 0.03 | 0.04 | 0.00 |
After reviewing the key financial ratios for Archean Chemical Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 13.13. This value is within the healthy range. It has decreased from 25.90 (Mar 24) to 13.13, marking a decrease of 12.77.
- For Diluted EPS (Rs.), as of Mar 25, the value is 13.12. This value is within the healthy range. It has decreased from 25.87 (Mar 24) to 13.12, marking a decrease of 12.75.
- For Cash EPS (Rs.), as of Mar 25, the value is 19.57. This value is within the healthy range. It has decreased from 31.55 (Mar 24) to 19.57, marking a decrease of 11.98.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 151.02. It has increased from 137.89 (Mar 24) to 151.02, marking an increase of 13.13.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 151.02. It has increased from 137.89 (Mar 24) to 151.02, marking an increase of 13.13.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 84.34. It has decreased from 107.79 (Mar 24) to 84.34, marking a decrease of 23.45.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 28.47. This value is within the healthy range. It has decreased from 41.00 (Mar 24) to 28.47, marking a decrease of 12.53.
- For PBIT / Share (Rs.), as of Mar 25, the value is 22.04. This value is within the healthy range. It has decreased from 35.30 (Mar 24) to 22.04, marking a decrease of 13.26.
- For PBT / Share (Rs.), as of Mar 25, the value is 18.13. This value is within the healthy range. It has decreased from 34.62 (Mar 24) to 18.13, marking a decrease of 16.49.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 13.14. This value is within the healthy range. It has decreased from 25.85 (Mar 24) to 13.14, marking a decrease of 12.71.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 13.14. This value is within the healthy range. It has decreased from 25.85 (Mar 24) to 13.14, marking a decrease of 12.71.
- For PBDIT Margin (%), as of Mar 25, the value is 33.75. This value is within the healthy range. It has decreased from 38.04 (Mar 24) to 33.75, marking a decrease of 4.29.
- For PBIT Margin (%), as of Mar 25, the value is 26.13. This value exceeds the healthy maximum of 20. It has decreased from 32.75 (Mar 24) to 26.13, marking a decrease of 6.62.
- For PBT Margin (%), as of Mar 25, the value is 21.49. This value is within the healthy range. It has decreased from 32.11 (Mar 24) to 21.49, marking a decrease of 10.62.
- For Net Profit Margin (%), as of Mar 25, the value is 15.57. This value exceeds the healthy maximum of 10. It has decreased from 23.98 (Mar 24) to 15.57, marking a decrease of 8.41.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 15.57. This value is within the healthy range. It has decreased from 23.98 (Mar 24) to 15.57, marking a decrease of 8.41.
- For Return on Networth / Equity (%), as of Mar 25, the value is 8.69. This value is below the healthy minimum of 15. It has decreased from 18.74 (Mar 24) to 8.69, marking a decrease of 10.05.
- For Return on Capital Employeed (%), as of Mar 25, the value is 12.38. This value is within the healthy range. It has decreased from 22.67 (Mar 24) to 12.38, marking a decrease of 10.29.
- For Return On Assets (%), as of Mar 25, the value is 6.77. This value is within the healthy range. It has decreased from 15.51 (Mar 24) to 6.77, marking a decrease of 8.74.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.08. This value is below the healthy minimum of 0.2. It has increased from 0.03 (Mar 24) to 0.08, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.09. This value is within the healthy range. It has increased from 0.03 (Mar 24) to 0.09, marking an increase of 0.06.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.46. It has decreased from 0.69 (Mar 24) to 0.46, marking a decrease of 0.23.
- For Current Ratio (X), as of Mar 25, the value is 3.50. This value exceeds the healthy maximum of 3. It has decreased from 5.38 (Mar 24) to 3.50, marking a decrease of 1.88.
- For Quick Ratio (X), as of Mar 25, the value is 2.65. This value exceeds the healthy maximum of 2. It has decreased from 4.44 (Mar 24) to 2.65, marking a decrease of 1.79.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.42. This value is below the healthy minimum of 4. It has increased from 0.32 (Mar 24) to 0.42, marking an increase of 0.10.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 17.37 (Mar 24) to 0.00, marking a decrease of 17.37.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 14.23 (Mar 24) to 0.00, marking a decrease of 14.23.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 82.63 (Mar 24) to 0.00, marking a decrease of 82.63.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 85.77 (Mar 24) to 0.00, marking a decrease of 85.77.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 43.37. This value is within the healthy range. It has decreased from 59.80 (Mar 24) to 43.37, marking a decrease of 16.43.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 25.97. This value is within the healthy range. It has decreased from 38.70 (Mar 24) to 25.97, marking a decrease of 12.73.
- For Enterprise Value (Cr.), as of Mar 25, the value is 6,487.30. It has decreased from 8,283.52 (Mar 24) to 6,487.30, marking a decrease of 1,796.22.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 6.23. This value exceeds the healthy maximum of 3. There is no change compared to the previous period (Mar 24) which recorded 6.23.
- For EV / EBITDA (X), as of Mar 25, the value is 18.46. This value exceeds the healthy maximum of 15. It has increased from 16.37 (Mar 24) to 18.46, marking an increase of 2.09.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 6.11. This value exceeds the healthy maximum of 3. It has decreased from 6.22 (Mar 24) to 6.11, marking a decrease of 0.11.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 82.62 (Mar 24) to 0.00, marking a decrease of 82.62.
- For Price / BV (X), as of Mar 25, the value is 3.41. This value exceeds the healthy maximum of 3. It has decreased from 4.86 (Mar 24) to 3.41, marking a decrease of 1.45.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 6.11. This value exceeds the healthy maximum of 3. It has decreased from 6.22 (Mar 24) to 6.11, marking a decrease of 0.11.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Archean Chemical Industries Ltd:
- Net Profit Margin: 15.57%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 12.38% (Industry Average ROCE: 13.95%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.69% (Industry Average ROE: 10.65%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 25.97
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.65
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 33.3 (Industry average Stock P/E: 175.63)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.09
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 15.57%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Inorganic - Others | No. 2, North Crescent Road, Chennai (Madras) Tamil Nadu 600017 | info@archeanchemicals.com http://www.archeanchemicals.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ranjit Pendurthi | Managing Director |
| Mr. Ravi Pendurthi | Non Independent Director |
| Mr. Subrahmanyam Meenakshisundaram | Non Independent Director |
| Ms. Padma Chandrasekaran | Independent Director |
| Mr. Chittoor Ghatambu Sethuram | Independent Director |
| Mr. Kandheri Munaswami Mohandass | Independent Director |